Last reviewed 2026-04-19 · How we verify

Myelofibrosis

Approved treatments

• Inrebic · Bristol-Myers Squibb
  Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs.
• Inrebic · Bristol-Myers Squibb
  Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells.
• Vonjo · Sobi
  Vonjo works by blocking the activity of the JAK2 enzyme, which is overactive in myelofibrosis patients.
• Jakafi · Incyte Corp

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Myelofibrosis treatment landscape brief
• Myelofibrosis treatment updates RSS